• Good-Risk Acute Myeloid Leukemia

  • Apr 14 2022
  • Durée: 22 min
  • Podcast

Good-Risk Acute Myeloid Leukemia

  • Résumé

  • Drs Gail Roboz and Gautam Borthakur discuss good-risk acute myeloid leukemia.

    Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/964531). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Diagnosis and Management of AML in Adults: 2017 ELN Recommendations From an International Expert Panel https://ashpublications.org/blood/article/129/4/424/36196/Diagnosis-and-management-of-AML-in-adults-2017-ELN

    Refinement of Cytogenetic Classification in Acute Myeloid Leukemia: Determination of Prognostic Significance of Rare Recurring Chromosomal Abnormalities Among 5876 Younger Adult Patients Treated in the United Kingdom Medical Research Council Trials https://ashpublications.org/blood/article/116/3/354/27618/Refinement-of-cytogenetic-classification-in-acute

    Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7030890/

    2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document From the European LeukemiaNet MRD Working Party https://pubmed.ncbi.nlm.nih.gov/34724563/

    Venetoclax Plus Intensive Chemotherapy With Cladribine, Idarubicin, and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome: A Cohort From a Single-Centre, Single-Arm, Phase 2 Trial https://pubmed.ncbi.nlm.nih.gov/34329576/

    Core Binding Factor Acute Myelogenous Leukemia-2021 Treatment Algorithm https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209225/

    Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission https://www.nejm.org/doi/full/10.1056/NEJMoa2004444

    NCCN Guidelines Version 1.2022: Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411

    Voir plus Voir moins

Ce que les auditeurs disent de Good-Risk Acute Myeloid Leukemia

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.